Clinical evaluation of autonomous, unsupervised planning integrated in MR-guided radiotherapy for prostate cancer.
Automatic segmentation
Autonomous radiotherapy planning
MR-Linac
MR-guided-RT
Particle swarm optimization
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
15
10
2021
revised:
04
01
2022
accepted:
25
01
2022
pubmed:
9
2
2022
medline:
8
4
2022
entrez:
8
2
2022
Statut:
ppublish
Résumé
This retrospective study aimed at clinical evaluation of autonomous radiotherapy planning for ten prostate cancer cases, including organ-at-risk/target contouring and treatment planning. Five experts scored the clinical acceptability of each step using a 4-level Likert-scale resulting in 78%, 66% and 90% acceptance. For 6/10 patients the entire workflow was considered acceptable.
Identifiants
pubmed: 35134447
pii: S0167-8140(22)00062-7
doi: 10.1016/j.radonc.2022.01.036
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
229-233Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest The Department of Radiation Oncology Tübingen receives within the frame of research agreements financial and technical support as well as sponsoring for travels and scientific symposia from Elekta AB (Stockholm, Sweden), TheraPanacea (Paris, France), Philips GmbH (Best, The Netherlands); Dr. Sennewald Medizintechnik GmbH (München, Germany), PTW Freiburg (Germany).